Investindustrial’s Acquisition of HTL-Strefa

EQT V and management were advised by J.P. Morgan, Kirkland & Ellis and EY.

EQT V (or “EQT”) has agreed to sell HTL-Strefa S.A. (“HTL”) to Investindustrial. Following the acquisition, HTL will be combined with PIC (, Artsana’s healthcare business acquired by Investindustrial in 2016. HTL is a fast-growing medtech company and pioneer in medical sharp devices, providing critical medical products across more than 80 countries globally addressing continuously growing healthcare needs.

EQT V acquired HTL in December 2009 with the strategy to strengthen HTL’s position as the global market leader in blood micro-sampling devices while expanding into adjacent product categories. The new management team, led by Mikkel Danvold, accelerated the transformation of HTL into a customer-centric innovative medtech company offering superior solutions to its customers. The transformation has been accomplished by driving a strong commercial agenda throughout the organization and by leveraging the superior quality and operational fundamentals of HTL. Expansion into multiple adjacent market segments, supported by increased investments in product development and production capacity have allowed HTL to experience strong organic growth and increased profitability.

From 2009 to March 2018 LTM, revenues doubled to approximately EUR 82 million and adjusted EBITDA more than doubled. Already in 2017 HTL doubled its revenue and EBITDA growth versus previous years and in the first quarter of 2018 alone, HTL has further accelerated growth to 4x historical growth rates.

The transaction is subject to approval from the relevant authorities and is expected to close in Q3 2018.

Chiomenti and Wardynski advised Investindustrial on the deal.

Kirkland & Ellis is advising EQT Partners with a team including Roger Johnson and Joel Arnell (Picture).

Involved fees earner: Roger Johnson – Kirkland & Ellis; Joel Arnell – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: EQT Partners;